.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Segment 1: Considering the Value of Diagnostic Tests

Published on: January 27, 2015

Panel moderator Surabhi Dangi-Garimella, PhD, managing editor of AJMC's Evidence-Based series, starts the panel discussion with a discussion about how payers and physicians evaluate the value of a particular diagnostic test.

Panel moderator Surabhi Dangi-Garimella, PhD, managing editor of AJMC’s Evidence-Based series, starts the panel discussion with a discussion about how payers and physicians evaluate the value of a particular diagnostic test.

The problem with new genomic next-generation sequencing clinical studies is that use in the last few years is not based on clinical or outcomes, Francisco J. Esteva, MD, PhD, said.

“Outcomes in a particular relevant patient population used to be and it should be our most factor, but I’m not sure that’s what’s happening today,” he said.